Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study - PubMed

4 hours ago

Telitacicept showed promising efficacy in IgA nephropathy (IgAN) by significantly reducing proteinuria and stabilizing eGFR.
A retrospective study of 68 IgAN patients found significant proteinuria reductions at 1 month, sustained over 6 months, with stable eGFR throughout follow-up.
Subgroup analyses based on baseline proteinuria, eGFR, gender, age, and therapy options revealed no significant differences in proteinuria reduction rates.
Patients with prior treatment failure also benefited, showing reduced proteinuria and improved eGFR slope, slowing annual decline from 6.35 to 3.68 ml/min/1.73m²/year.
Compared to supportive care alone, Telitacicept led to greater proteinuria reduction, and therapy was well-tolerated with a favorable safety profile.
Telitacicept treatment decreased urinary Gd-IgA1/Cr levels, and responsive patients had higher IgA levels than non-responsive ones.

Hasty Briefsbeta